A.E. Whiteley, T.T. Price, G. Cantelli, D.A. Sipkins, Leukaemia: a model metastatic disease. Nat. Rev. Cancer 21, 461–475 (2021)
CAS PubMed PubMed Central Google Scholar
R. Seth, A. Singh, Leukemias in children. Indian J. Pediatr. 82, 817–824 (2015)
H. Sung, J. Ferlay, R.L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal, F. Bray, Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249 (2021)
F. Malard, M. Mohty, Acute lymphoblastic leukaemia. Lancet 395, 1146–1162 (2020)
Stat bite: estimated new leukemia cases in 2008. J. Natl. Cancer Inst. 100, 531 (2008)
S.P. Hunger, X. Lu, M. Devidas, B.M. Camitta, P.S. Gaynon, N.J. Winick, G.H. Reaman, W.L. Carroll, Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children’s oncology group. J. Clin. Oncol. 30, 1663–1669 (2012)
PubMed PubMed Central Google Scholar
D. Pulte, A. Gondos, H. Brenner, Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century. Blood 113, 1408–1411 (2009)
D. Pulte, L. Jansen, A. Gondos, A. Katalinic, B. Barnes, M. Ressing, B. Holleczek, A. Eberle, H. Brenner, G.C.S.W. Group, Survival of adults with acute lymphoblastic leukemia in Germany and the United States. PLoS One 9, e85554 (2014)
PubMed PubMed Central Google Scholar
C.H. Pui, D. Campana, D. Pei, W.P. Bowman, J.T. Sandlund, S.C. Kaste, R.C. Ribeiro, J.E. Rubnitz, S.C. Raimondi, M. Onciu, E. Coustan-Smith, L.E. Kun, S. Jeha, C. Cheng, S.C. Howard, V. Simmons, A. Bayles, M.L. Metzger, J.M. Boyett, W. Leung, R. Handgretinger, J.R. Downing, W.E. Evans, M.V. Relling, Treating childhood acute lymphoblastic leukemia without cranial irradiation. N. Engl. J. Med. 360, 2730–2741 (2009)
CAS PubMed PubMed Central Google Scholar
T.A. de Beaumais, E. Jacqz-Aigrain, Intracellular disposition of methotrexate in acute lymphoblastic leukemia in children. Curr. Drug. Metab. 13, 822–834 (2012)
J.M. Rowe, G. Buck, A.K. Burnett, R. Chopra, P.H. Wiernik, S.M. Richards, H.M. Lazarus, I.M. Franklin, M.R. Litzow, N. Ciobanu, H.G. Prentice, J. Durrant, M.S. Tallman, A.H. Goldstone, Ecog, M.N.A.L.W. Party, Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood 106, 3760–3767 (2005)
J.J. Cornelissen, D. Blaise, Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood 127, 62–70 (2016)
Y.R. Ma, L.P. Xu, X.H. Zhang, C.H. Yan, Y. Wang, F.R. Wang, J.Z. Wang, Y. Chen, W. Han, Y.H. Chen, H. Chen, K.Y. Liu, X.J. Huang, Comparable post-relapse outcomes between haploidentical and matched related donor allogeneic stem cell transplantation. Bone Marrow Transplant. 52, 409–414 (2017)
A. de Labarthe, P. Rousselot, F. Huguet-Rigal, E. Delabesse, F. Witz, S. Maury, D. Rea, J.M. Cayuela, M.C. Vekemans, O. Reman, A. Buzyn, A. Pigneux, M. Escoffre, Y. Chalandon, E. MacIntyre, V. Lheritier, J.P. Vernant, X. Thomas, N. Ifrah, H. Dombret, L. Group for Research on Adult Acute Lymphoblastic, Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood 109, 1408–1413 (2007)
F. Ravandi, S.M. O’Brien, J.E. Cortes, D.M. Thomas, R. Garris, S. Faderl, J.A. Burger, M.E. Rytting, A. Ferrajoli, W.G. Wierda, S. Verstovsek, R. Champlin, P. Kebriaei, D.A. McCue, X. Huang, E. Jabbour, G. Garcia-Manero, Z. Estrov, H.M. Kantarjian, Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer 121, 4158–4164 (2015)
R.J. Brentjens, M.L. Davila, I. Riviere, J. Park, X. Wang, L.G. Cowell, S. Bartido, J. Stefanski, C. Taylor, M. Olszewska, O. Borquez-ojeda, J. Qu, T. Wasielewska, Q. He, Y. Bernal, I.V. Rijo, C. Hedvat, R. Kobos, K. Curran, P. Steinherz, J. Jurcic, T. Rosenblat, P. Maslak, M. Frattini, M. Sadelain, CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 5, 177ra138 (2013)
N.C. Munshi, L.D. Anderson Jr., N. Shah, D. Madduri, J. Berdeja, S. Lonial, N. Raje, Y. Lin, D. Siegel, A. Oriol, P. Moreau, I. Yakoub-Agha, M. Delforge, M. Cavo, H. Einsele, H. Goldschmidt, K. Weisel, A. Rambaldi, D. Reece, F. Petrocca, M. Massaro, J.N. Connarn, S. Kaiser, P. Patel, L. Huang, T.B. Campbell, K. Hege, J. San-Miguel, Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384, 705–716 (2021)
R.C. Sterner, R.M. Sterner, CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 11, 69 (2021)
PubMed PubMed Central Google Scholar
J.H. Park, I. Riviere, M. Gonen, X. Wang, B. Senechal, K.J. Curran, C. Sauter, Y. Wang, B. Santomasso, E. Mead, M. Roshal, P. Maslak, M. Davila, R.J. Brentjens, M. Sadelain, Long-term follow-up of CD19 CAR therapy in acute lymphoblastic. Leukemia N. Engl. J. Med. 378, 449–459 (2018)
S.L. Maude, T.W. Laetsch, J. Buechner, S. Rives, M. Boyer, H. Bittencourt, P. Bader, M.R. Verneris, H.E. Stefanski, G.D. Myers, M. Qayed, B. De Moerloose, H. Hiramatsu, K. Schlis, K.L. Davis, P.L. Martin, E.R. Nemecek, G.A. Yanik, C. Peters, A. Baruchel, N. Boissel, F. Mechinaud, A. Balduzzi, J. Krueger, C.H. June, B.L. Levine, P. Wood, T. Taran, M. Leung, K.T. Mueller, Y. Zhang, K. Sen, D. Lebwohl, M.A. Pulsipher, S.A. Grupp, Tisagenlecleucel in children and young adults with B-cell lymphoblastic Leukemia. N. Engl. J. Med. 378, 439–448 (2018)
CAS PubMed PubMed Central Google Scholar
A. Bozorgi, M. Bozorgi, M. Khazaei, Immunotherapy and immunoengineering for breast cancer; a comprehensive insight into CAR-T cell therapy advancements, challenges and prospects. Cell Oncol. Dordr. 45, 755–777 (2022)
M. Akhoundi, M. Mohammadi, S.S. Sahraei, M. Sheykhhasan, N. Fayazi, CAR T cell therapy as a promising approach in cancer immunotherapy: challenges and opportunities. Cell Oncol. Dordr. 44, 495–523 (2021)
K.M. Murphy, C.A. Nelson, J.R. Sedy, Balancing co-stimulation and inhibition with BTLA and HVEM. Nat. Rev. Immunol. 6, 671–681 (2006)
J.I. Rodriguez-Barbosa, P. Schneider, A. Weigert, K.M. Lee, T.J. Kim, J.A. Perez-Simon, M.L. Del Rio, HVEM, a cosignaling molecular switch, and its interactions with BTLA, CD160 and LIGHT. Cell Mol. Immunol. 16, 679–682 (2019)
CAS PubMed PubMed Central Google Scholar
T.L. Murphy, K.M. Murphy, Slow down and survive: enigmatic immunoregulation by BTLA and HVEM. Annu. Rev. Immunol. 28, 389–411 (2010)
N. Watanabe, M. Gavrieli, J.R. Sedy, J. Yang, F. Fallarino, S.K. Loftin, M.A. Hurchla, N. Zimmerman, J. Sim, X. Zang, T.L. Murphy, J.H. Russell, J.P. Allison, K.M. Murphy, BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat. Immunol. 4, 670–679 (2003)
L.C. Gonzalez, K.M. Loyet, J. Calemine-Fenaux, V. Chauhan, B. Wranik, W. Ouyang, D.L. Eaton, A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator. Proc. Natl. Acad. Sci. U. S. A. 102, 1116–1121 (2005)
CAS PubMed PubMed Central Google Scholar
T. Duhen, C. Pasero, F. Mallet, B. Barbarat, D. Olive, R.T. Costello, LIGHT costimulates CD40 triggering and induces immunoglobulin secretion; a novel key partner in T cell-dependent B cell terminal differentiation. Eur. J. Immunol. 34, 3534–3541 (2004)
Y. Morel, A. Truneh, R.W. Sweet, D. Olive, R.T. Costello, The TNF superfamily members LIGHT and CD154 (CD40 ligand) costimulate induction of dendritic cell maturation and elicit specific CTL activity. J. Immunol. 167, 2479–2486 (2001)
D.N. Mauri, R. Ebner, R.I. Montgomery, K.D. Kochel, T.C. Cheung, G.L. Yu, S. Ruben, M. Murphy, R.J. Eisenberg, G.H. Cohen, P.G. Spear, C.F. Ware, LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator. Immunity 8, 21–30 (1998)
R.J. Schilder, J.D. Powderly, H. Park, M.A. Bilen, M. McKean, R. May, H. Feng, S. Yao, P. Keegan, A. Naing, Phase Ia dose-escalation study of the anti-BTLA antibody icatolimab as a monotherapy in patients with advanced solid tumor. J. Clin. Oncol. 40 (2022)
Z. Wang, L. Wu, B. Li, Y. Cheng, X. Li, X. Wang, L. Han, X. Wu, Y. Fan, Y. Yu, D. Lv, J. Shi, J. Huang, S. Zhou, B. Han, G. Sun, Q. Guo, Y. Ji, X. Zhu, S. Hu, W. Zhang, Q. Wang, Y. Jia, Z. Wang, Y. Song, J. Wu, M. Shi, X. Li, Z. Han, Y. Liu, Z. Yu, A.W. Liu, X. Wang, C. Zhou, D. Zhong, L. Miao, Z. Zhang, H. Zhao, J. Yang, D. Wang, Y. Wang, Q. Li, X. Zhang, M. Ji, Z. Yang, J. Cui, B. Gao, B. Wang, H. Liu, L. Nie, M. He, S. Jin, W. Gu, Y. Shu, T. Zhou, J. Feng, X. Yang, C. Huang, B. Zhu, Y. Yao, X. Tang, J. Yu, E. Maher, H. Feng, S. Yao, P. Keegan, J. Wang, Toripalimab plus chemotherapy for patients with treatment-naive advanced non-small-cell lung cancer: a multicenter randomized phase III trial (CHOICE-01). J. Clin. Oncol. 41, 651–663 (2023)
P.G. Spear, Herpes simplex virus: receptors and ligands for cell entry. Cell Microbiol. 6, 401–410 (2004)
N. Malissen, N. Macagno, S. Granjeaud, C. Granier, V. Moutardier, C. Gaudy-Marqueste, N. Habel, M. Mandavit, B. Guillot, C. Pasero, E. Tartour, R. Ballotti, J.J. Grob, D. Olive, HVEM has a broader expression than PD-L1 and constitutes a negative prognostic marker and potential treatment target for melanoma. Oncoimmunology 8, e1665976 (2019)
PubMed PubMed Central Google Scholar
M.Z. Han, S. Wang, W.B. Zhao, S.L. Ni, N. Yang, Y. Kong, B. Huang, A.J. Chen, X.G. Li, J. Wang, D.H. Wang, Immune checkpoint molecule herpes virus entry mediator is overexpressed and associated with poor prognosis in human glioblastoma. EBioMed. 43, 159–170 (2019)
Comments (0)